Bayer, Novartis Settle MS Drug Dispute For $200M

Law360, New York (March 26, 2007, 12:00 AM EDT) -- After years of negotiations, drug makers Bayer AG and Novartis AG finally settled their dispute over multiple sclerosis drug Betaseron on Monday, agreeing to give Bayer full control of the product and to let Novartis launch its own version in 2009.

Betaseron, also known as Interferon beta-1b, is used to treat relapsing forms of multiple sclerosis. It is a big moneymaker for Bayer, drawing €1 billion ($1.3 million) in sales in 2006.

Under the agreement, Bayer will pay around $200 million for the transfer of production...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.